6 documents found, page 1 of 1
Urgent request for pretomanid label expansion to align with WHO guidelines and ...
Kuksa, L; Andrejak, C; Haecker, B; Bothamley, G; Calcagno, A; Cirillo, DM; Duarte, R; Fatima, R; Ferlazzo, G; Guglielmetti, L; Günther, G; Hewison, CPretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, “when antibiotics used for the latter form of TB do not work or cause unacceptable side effects.” This restricted use implies...
Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in E...
Kirakosyan, O; Reimann, M; Andersen, AB; Bjarnason, A; Bakos, Á; Dyrhol-Riise, AM; McLaughlin, AM; Nita, C; Pieridou, D; Chesov, D; Davidavičienė, EV"Background: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region. Methods: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of putative hepatoprotective agents in patients receiving TB treatment among Tuberculosis Network European Trials Group ...
Tuberculosis incidence in foreign-born people residing in European countries in...
Vasiliu, A; Köhler, N; Altpeter, E; Ægisdóttir, TR; Amerali, M; de Oñate, WA; Bakos, Á; D'Amato, S; Cirillo, DM; van Crevel, R; Davidaviciene, E"Background European-specific policies for tuberculosis (TB) elimination require identification of key populations that benefit from TB screening. Aim We aimed to identify groups of foreign-born individuals residing in European countries that benefit most from targeted TB prevention screening. Methods The Tuberculosis Network European Trials group collected, by cross-sectional survey, numbers of foreign-born TB...
Rifapentine access in Europe: growing concerns over key tuberculosis treatment ...
Guglielmetti, L; Günther, G; Leu, C; Cirillo, D; Duarte, R; Garcia-Basteiro, AL; Goletti, D; Jankovic, M; Kuksa, L; Maurer, FP; Méchaï, F; Tiberi, S[No abstract available]
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Co...
van Leth, F; Brinkmann, F; Cirillo, DM; Dheda, K; Duarte, R; Guglielmetti, L; Kuksa, L; Lange, C; Mitnick, C; Skrahina, A; Zaman, K; Bothamley, Gn/a
Management of patients with multidrug-resistant tuberculosis
Lange, C; Aarnoutse, RE; Alffenaar, JWC; Bothamley, G; Brinkmann, F; Costa, J; Chesov, D; van Crevel, R; Dedicoat, M; Dominguez, J; Duarte, RThe emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, t...